Clinical Trials Logo
  1. Home
  2. Astrocytoma, Grade III
  3. NCT03450850

Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma

Astrocytoma, Grade III Clinical Trial

Official title:
Phase II, Single Arm Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent WHO Grade III Malignant Astrocytoma

Clinical Trial Summary

This is a Phase 2 study in subjects with WHO Grade III Anaplastic Astrocytoma (G3 astrocytoma) who had progressive disease during first or second line treatment and who have not previously received any BEV or any experimental agents.

Clinical Trial Description

Primary Objective: The primary objective will be to determine the efficacy of NOVOTTF-200A in recurrent anaplastic astrocytoma patients (6-month progression-free survival) Secondary Objectives: - To evaluate the safety of NOVOTTF-200A in the subject population. - To evaluate efficacy of NOVOTTF-200A in the subject population. - To see if the presence of ATRX, TERT promoter, IDH1 mutations and/or MGMT promoter methylation, confers a better response to NOVOTTF-200A. - To determine if the treatment significantly modifies the patient's quality of life. Sponsor will use the Functional Assessment of Cancer Therapy (FACT) questionnaires: - FACT-Brain (FACT-Br) - FACT-Cognitive Function (FACT-Cog) Exploratory Objectives: - To determine if the presence of proneural or mesenchymal phenotype (Cytoscan analysis) confers a better response to NovoTTF. - To determine if the in vitro sensitivity of the glioma cells derived from patient specimens before and after the NOVOTTF-200A treatment correlates with the patient's response to treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03450850
Study type Interventional
Source University of California, Irvine
Contact
Status Active, not recruiting
Phase N/A
Start date May 21, 2020
Completion date September 2024
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02655601 - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Phase 2
Completed NCT02644291 - Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors Phase 1
Terminated NCT03906448 - FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma Phase 2
Recruiting NCT05765812 - A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT04757662 - Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma Phase 1
Not yet recruiting NCT06161974 - Study of Olutasidenib and Temozolomide in HGG Phase 2
Completed NCT03224104 - Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma Phase 1
Terminated NCT02722512 - Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine Phase 1
Recruiting NCT06118723 - The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Withdrawn NCT03956706 - Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas N/A
Recruiting NCT03596086 - HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM Phase 1/Phase 2
Recruiting NCT04304300 - Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes
Completed NCT03072134 - Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma Phase 1